Skip to content
Study details
Enrolling now

DOMINICA Trial

AstraZeneca
NCT IDNCT05692180ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

200

Study length

about 9.1 years

Ages

6–18

Locations

28 sites in AL, AR, AZ +16

About this study

This trial is testing benralizumab, a drug given by injection, in children with severe asthma. The goal is to see if benralizumab helps reduce the frequency of asthma attacks compared to a placebo.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Benralizumab
  • 2.Take Placebo
PhasePhase 3
DrugBenralizumab

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

benralizumab

Endpoints

Secondary: Change from baseline, during the DB treatment period in Asthma symptom score, Change from baseline, during the DB treatment period in Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA), Change from baseline, during the DB treatment period in Paediatric Asthma Quality of Life Questionnaire-Interviewer Administered (PAQLQ-IA) total score, Change from baseline, during the DB treatment period in night-time awakenings due to asthma, Change from baseline, during the DB treatment period in peak expiratory flow (PEF), Change from baseline, during the DB treatment period in rescue medication use, Change from baseline, during the DB treatment period, in spirometry, for post-bronchodilator FEV1, Change from baseline, during the DB treatment period, in spirometry, for pre-dose/pre-bronchodilator forced expiratory volume in one second (FEV1)

Body systems

Respiratory